Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michail Vernardos"'
Autor:
Ioannis Anastasiou, Alexandros Patrianakos, Michail Vernardos, Emmanouil Foukarakis, Michail Pitarokoilis, Stylianos Petousis, Evangelos Zacharis, Maria Marketou, Emmanouil Skalidis, George Kochiadakis, Fragkiskos Parthenakis, Panos Vardas, Michalis Hamilos
Publikováno v:
American Heart Journal Plus, Vol 23, Iss , Pp 100222- (2022)
Introduction: Ticagrelor has been established as the P2Y12-inhibitor of choice in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI); however, its use has not been adequately studie
Externí odkaz:
https://doaj.org/article/52355da208564f7e80fd574c757420ac
Autor:
Paris-Dimitrios Kalogerakos, Konstantinos Lasithiotakis, Michail Vernardos, Lambros Lazopoulos, Anastasios Koutsopoulos, George Lazopoulos
Publikováno v:
Oxford Medical Case Reports. 2022
Cardiac amyloidosis has been strongly associated with postoperative intractable circulatory failure, and intestinal amyloidosis could lead to intestinal pseudo-obstruction. The latter can be treated with neostigmine, which is notorious for its brief
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a74f8212efe8b5dee27f452b24568b6
https://doi.org/10.1093/omcr/omac031
https://doi.org/10.1093/omcr/omac031
Autor:
Konstantinos Gatzoulis, Vassilios Vassilikos, Skevos Sideris, Konstantinos Trachanas, Petros Arsenos, Dimitrios Tsiachris, Emmanouil Simantirakis, Christos-Konstantinos Antoniou, Ioannis Kallikazaros, Iosif Xenogiannis, Michail Vernardos, Ioannis Konstantinou, Konstantinos Triantafyllou, Konstantinos Vlachos, Emmanuel M. Kanoupakis, Panagiotis Korantzopoulos, Athanasios Saplaouras, Nikolaos Fragakis, Antonios Sideris, Ioannis Goudevenos, Efstathios K. Iliodromitis, Panagiota Flevari, Polychronis Dilaveris, Konstantinos Tsimos, Dimitrios Tousoulis
Publikováno v:
European Heart Journal
Aims Sudden cardiac death (SCD) annual incidence is 0.6–1% in post-myocardial infarction (MI) patients with left ventricular ejection fraction (LVEF)≥40%. No recommendations for implantable cardioverter-defibrillator (ICD) use exist in this popul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::747e40c43f2a290748aea1079831103c
https://pubmed.ncbi.nlm.nih.gov/31230065
https://pubmed.ncbi.nlm.nih.gov/31230065